Professor, Medicine (Hematology), Yale School of Medicine
Oncology
Dr. Steven D. Gore, MD
|
|
Give Review
Steven D. Gore, MD is an expert in the field of Oncology. He graduated from Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Steven Gore is a published doctor. He has 75 papers published. The most current publication "Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database." Steven Gore accepts Medicare payments and is listed with Medicare.gov.
Publications
- Lost in translation? Ten years of development of histone deacetylase inhibitors in Acute myeloid leukemia and myelodysplastic syndromes.
- Intensity of end-of-life care for patients with Myelodysplastic syndromes: Findings from a large national database.
- Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
- Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part d.
- Current state of prognostication and risk stratification in Myelodysplastic syndromes.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular Lymphoma.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- New strategies in Acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
- Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with Myelodysplastic syndromes and oligoblasti...
- Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients wi...
- Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes.
- Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk Acute promyelocytic leukaemia may eliminate the need for maintenance...
- Risk stratification in Myelodysplastic syndromes: is there a role for gene expression profiling?
- Should elderly patients with higher-risk Myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?
- Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with Myelodysplastic syndromes.
- A multivariate analysis of the relationship between response and survival among patients with higher-risk Myelodysplastic syndromes treated within azacitidine or conve...
- Current therapy of Myelodysplastic syndromes.
- Myelodysplastic syndromes: What do hospitalists need to know?
- Treatment and outcomes for chronic myelomonocytic Leukemia compared to myelodysplastic syndromes in older adults.
- Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with Myelodysplastic syndromes and consistency with clinical guidelines.
- Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
- Sustained remission in a patient with Myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblasti...
- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed...
- Epigenetic therapies in MDS and AML.
- Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with Myelodysplastic syndromes.
- Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed Acute myelogenous leukemia.
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure.
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk Myelodysplastic syndromes.
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia.
- Myelodysplastic syndromes: where do we go from here?
- 5-azacytidine as salvage treatment in relapsed Myeloid tumors after allogeneic bone marrow transplantation.
- Aberrant epigenetic and genetic marks are seen in Myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for Acute leukemias.
- Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin Lymphomas.
- Treatment of Acute promyelocytic leukemia for older patients.
- Role of allogeneic transplantation for FLT3/ITD Acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
- New ways to use DNA methyltransferase inhibitors for the treatment of Myelodysplastic syndrome.
- NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes.
- Epigenetic differences in cytogenetically normal versus abnormal Acute myeloid leukemia.
- Novel approaches for Myelodysplastic syndromes: beyond hypomethylating agents.
- Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of Acute promyelocytic leukemia.
- NCCN Task Force: Transfusion and iron overload in patients with Myelodysplastic syndromes.
- Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced Myeloid malignancies.
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
- Enhancing survival outcomes in the management of patients with higher-risk Myelodysplastic syndromes.
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with Myeloid malignancies.
- MicroRNA: mIR-ly regulators of DNMT?
- Active oral regimen for elderly adults with newly diagnosed Acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib...
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of Myelodysplastic syndromes: an evidence-based review.
- New agents for the treatment of AML recent study findings.
- Future directions in Myelodysplastic syndrome: newer agents and the role of combination approaches.
- Derepression in the desert: the third workshop on clinical translation of epigenetics in Cancer therapeutics.
- Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with Acute myelogenous leukemia and poor-risk features.
- DNA methyltransferase and histone deacetylase inhibitors in the treatment of Myelodysplastic syndromes.
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory Acute leukemias.
- Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk Acute myelogenous leukemia.
- Addition of histone deacetylase inhibitors in combination therapy.
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed Acute leukemias.
- Intravenous azacitidine for MDS.
- DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
- Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of Myeloid neoplasms.
- Myelodysplastic syndromes clinical practice guidelines in oncology.
- Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of Myelodysplastic syndromes.
- Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult Acute leukemias.
- Clinical translation of epigenetics in Cancer: eN-CORe--a report on the second workshop.
- Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
- Future directions for the use of hypomethylating agents.
- Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.
- Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in Acute promyelocytic leukemia.
- State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in Cancer January 2003.
- Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in Acute lymphoc...
- Myelodysplastic syndrome.
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and Acute myeloid leukemia.
Schools
Yale University
University of Chicago
Johns Hopkins Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Johns Hopkins University -
University of Chicago -
Yale University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Lyndsay N. Harris, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jill Lacy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott N. Gettinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin W. Hofstatter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey M. Stein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mario Sznol, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah B. Goldberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warren D. Shlomchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael E. Hurwitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard S. Hochster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward Chu, MD |